×

Pfizer-Medivation cash deal is hard to justify: Analyst

7:19 PM ET Mon, 22 Aug 2016

Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.